Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is 
Press Release
 View printer-friendly version << Back

Agios to Present at Leerink Partners Rare Disease Roundtable

CAMBRIDGE, Mass., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Leerink Partners 4th Annual Rare Disease Roundtable in New York on Wednesday, September 30, 2015 at 3:35 p.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

About Agios Pharmaceuticals

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic disorders of metabolism through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at agios.com.

CONTACT: Renee Leck, Senior Manager, Investor and
         Public Relations
         Renee.Leck@agios.com
         617-649-8299

Agios Pharmaceuticals logo

Agios Pharmaceuticals